In this issue:
- Faecal immunochemical and blood tests for CRC risk stratification
- Chromosome 18q11.2-q12.1 marker for bevacizumab use in mCRC
- Stop-gain mutation in GXYLT1 promotes CRC metastasis
- Pembrolizumab for MSI-H or dMMR mCRC
- Neoadjuvant chemotherapy for colorectal peritoneal metastases
- Endoscopic mucosal resection of large non-pedunculated colorectal polyps
- Trough regorafenib levels and OS in chemorefractory mCRC
- Antibiotic consumption and colon and rectal cancer development
- Bevacizumab + chemotherapy for brain-gut peptides, intestinal flora, and oxidative stress
- Multi-peptide vaccine + maintenance therapy in mCRC
Please login below to download this issue (PDF)